orphan nuclear receptor

orphan nuclear receptor

member of the family of nuclear hormone receptor that have no known ligand. Some (for example, steroidogenic factor 1, DAX-1) have been associated with human diseases.
References in periodicals archive ?
Nurr1, an orphan nuclear receptor, is a transcriptional activator of endogenous tyrosine hydroxylase in neural progenitor cells derived from the adult brain.
The keynote lecture provides an introduction to the nuclear receptor superfamily and the remaining contributions discuss such topics as metabolic control by LXR receptors, regulation of cardiac energetic by the orphan nuclear receptors ERR-alpha and ERR-gamma, FXR and bile acids as critical modulators of metabolisms, the role of PPARs in human prediabetes, the role of the intestine in reverse cholesterol transport, NR4A nuclear receptors in the vessel wall, cholesterol as a novel target in the treatment of Alzheimer's disease, PPAR-gamma mediated effects in central nervous system disorders, and the role of the orphan nuclear receptor rev-erb-alpha in the molecular biology of circadian rhythms and cardiometabolic disease.
The 5-LOX gene has been shown to carry a response element for the orphan nuclear receptor RORalpha (for its RORalpha1 isoform in particular) in its promoter region.
says that SRC-2 works with an orphan nuclear receptor ROR alpha to affect the activity of the sugar-converting enzyme, glucose-6-phosphatase in the liver.
An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway.
The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions.
It should also allow the continued development of the leading orphan nuclear receptor lead compounds in which Ligand continues to have a potential future royalty interest if successfully developed and marketed.
Control of the steroidogenic metabolic pathway is regulated partly by P450 cytochrome hydroxylases, and the expression of many of these enzymes is controlled by the orphan nuclear receptor, steroidogenic factor-1 (SF-1).
The primary directive of the NURSA program is to gather and organize information relating to key aspects of orphan nuclear receptor biology, with the aim of extending this blueprint to the wider discipline of nuclear receptor signaling.
Ligand has been a minority equity investor in X-Ceptor since 1999, when Ligand and a group of private investors formed the private company to further the development of orphan nuclear receptor technology to identify new drugs.
Ligand entered into its tenth collaboration with a global pharmaceutical company, received milestone payments based on the advancement of three major new compounds in two other collaborations, sublicensed to Roche certain patents rights acquired with Seragen, and completed funding of X-Ceptor, an independent spin-out of orphan nuclear receptor technology.